Nilofer Saba Azad, MD, discusses third-line treatment options for patients with colorectal cancer.
Nilofer Saba Azad, MD, associate professor of oncology, Johns Hopkins University School of Medicine, director, Developmental Therapeutics Clinical Trials Program, Johns Hopkins Sidney Kimmel Cancer Center, discusses third-line treatment options for patients with colorectal cancer (CRC).
Patients with KRAS wild-type CRC can receive EGFR inhibitors, Azad says.
Additionally, patients whose tumors harbor a BRAF mutation should be treated with a BRAF inhibitor in combination with an EGFR inhibitor, explains Azad.
For the general population of patients with CRC, treatment selection is between TAS-102 (trifluridine/tipiracil; Lonsurf) and regorafenib (Stivarga) in the third-line setting, concludes Azad.